All News

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug claims and underpaid pharmacies.

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 clinical trial of LHP588, a novel gingipain inhibitor targeting Porphyromonas Gingivalis, aimed at slowing Alzheimer's progression in infected patients by addressing a potential microbial cause of neuroinflammation and neurodegeneration

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and pediatric patients aged 12 years and older.

The Supreme Court has ruled 5-4 to allow the Trump administration’s NIH funding cuts to continue, impacting more than 1,700 medical research grants in areas including heart disease, HIV/AIDS, Alzheimer’s disease, and mental health.

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and potential additional consideration tied to closing net cash.

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea HD due to a major amendment stemming from a third-party manufacturing inspection. Despite the delay, Eylea HD remains available in the U.S., and Regeneron anticipates a swift resolution as they address manufacturing concerns and continue expanding treatment options.

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward regulatory approval and patient access.

A joint statement lays out the framework for a potential trade agreement.

Johnson & Johnson assures no impact on current treatments for multiple myeloma.

Staff members published an open letter to the HHS Secretary following a deadly shooting earlier this month.

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to innovative treatments and strengthen evidence-based healthcare.

The company is downsizing its gene therapy operations following reduced demand from a major client, even as industry reliance on CDMOs and CMOs for capacity and expertise continues to grow.

Jazz Pharmaceuticals partners with Saniona to develop SAN2355, a promising epilepsy treatment, enhancing options for neurological disorders.

The clinical hold is due to questions about BX004’s nebulizer device, temporarily pausing US enrollment in the cystic fibrosis Phase IIb trial (NCT06998043) while European dosing continues.

The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient evidence of efficacy in patients with Friedreich’s ataxia.

The comments came after the AAP announced its vaccine recommendations, which go against those of the CDC.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Ron Lanton, partner, Lanton Law, warns that ongoing lawsuits targeting vaccine policy could create ripple effects across FDA decision-making and reshape how future emergency use authorizations are granted.

Ron Lanton, partner, Lanton Law, warns that recent changes to federal vaccine recommendations could trigger extensive litigation as insurers, providers, and patients face new access and coverage challenges.

Rob Abbott, CEO, ISPOR, highlights how AI is streamlining research and improving patient care while stressing the importance of human oversight.

The AAP diverges from CDC guidelines, advocating for Covid-19 vaccines in young children, igniting debate over vaccine policy and public health integrity.

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation to boost efficiency, refocus on core businesses, and reinvest in high-priority programs.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing treatment options remain limited.

Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, through a groundbreaking clinical trial.

Whole genome sequencing market is projected to grow significantly, driven by advancements in technology and personalized medicine, reaching $6.1 billion by 2030.

Rob Abbott, CEO, ISPOR, highlights that the United States excels in areas like cancer screening and advanced medical technology while facing challenges such as rising costs, lack of universal coverage, and health outcomes that lag behind other high-income nations.